A5061172196- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Screening and Detection
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal and Anal Carcinomas
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Cancer survivorship and care
- Statistical Methods in Clinical Trials
- Nutrition and Health in Aging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Frailty in Older Adults
- Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Multiple and Secondary Primary Cancers
- Cancer therapeutics and mechanisms
- Intraperitoneal and Appendiceal Malignancies
- Cancer Immunotherapy and Biomarkers
University Medical Center Utrecht
2016-2025
Utrecht University
2016-2025
Netherlands Comprehensive Cancer Organisation
2015-2025
Heidelberg University
2013-2024
University Hospital Heidelberg
2013-2024
Dutch Colorectal Cancer Group
2024
St. Catherine University
2024
Maastricht University
2023
The Netherlands Cancer Institute
2007-2018
Fishwell Consulting (Australia)
2018
Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied effect of adding anti-epidermal receptor (EGFR) cetuximab to a combination capecitabine, oxaliplatin, and cancer.We randomly assigned 755 patients with previously untreated cancer (CB regimen, 378 patients) or same regimen weekly (CBC 377 patients). The primary end point was progression-free survival....
Abstract Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR) status its relation to BRAF mutation (BRAFMT) in metastatic colorectal cancer (mCRC). Experimental Design: A pooled analysis four phase III studies first-line treatment mCRC (CAIRO, CAIRO2, COIN, FOCUS) was performed. Primary outcome parameter hazard ratio (HR) for median progression-free survival (PFS) overall (OS) MMR BRAF. For analysis, Cox regression performed on individual patient data. Results:...
A deficient mismatch repair system (dMMR) is present in 10–20% of patients with sporadic colorectal cancer (CRC) and associated a favourable prognosis early stage disease. Data on advanced disease are scarce. Our aim was to investigate the incidence outcome dMMR CRC. were collected from phase III study 820 CRC patients. Expression proteins examined by immunohistochemistry. In addition microsatellite instability analysis performed methylation status MLH1 promoter assessed. We then correlated...
Synchronous metastases of colorectal cancer (CRC) are considered to be worse prognostic value compared with metachronous metastases, but only few and conflicting data have been reported on this issue. We retrospectively investigated patient demographics, primary tumour characteristics overall survival (OS) in 550 advanced CRC patients vs synchronous who participated the phase III CAIRO study. For purpose a prior resection were considered. The clinical pathological associated poor prognosis...
Recent transcriptomic analyses have identified four distinct molecular subtypes of colorectal cancer with evident clinical relevance. However, the requirement for sufficient quantities bulk tumor and difficulties in obtaining high-quality genome-wide transcriptome data from formalin-fixed paraffin-embedded tissue are obstacles toward widespread adoption this taxonomy. Here, we develop an immunohistochemistry-based classifier to validate prognostic predictive value subtyping a multicenter study.
Purpose Fatigue is a common problem among colon cancer patients and typically increases during chemotherapy. Exercise chemotherapy might have beneficial effects on fatigue. To investigate the short- long-term of an exercise program in adjuvant treatment, Physical Activity During Cancer Treatment study was conducted. Methods In this multicenter randomized controlled trial, 33 undergoing (21 men 12 women) were randomly assigned to either group receiving 18-wk supervised (n = 17) or usual care...
Estimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for trials. We constructed prognostic nomograms one-year overall survival six-month progression-free in metastatic colorectal carcinoma by using ARCAD database. Data from 22 674 patients 26 randomized phase III trials since 1997 were used to construct validate Cox models, stratified treatment arm within each study. Candidate variables included baseline age, sex, body...
Improvements in systemic cancer treatments have resulted more patients surviving for prolonged periods of time on treatment. This has made treatment-related toxicity and quality life concerns increasingly relevant. Hand-foot syndrome (HFS) is a common skin reaction to therapy that should be anticipated with chemotherapeutic such as pegylated liposomal doxorubicin, docetaxel, fluoropyrimidines. In this review we discuss current knowledge the diagnosis, incidence, pathogenesis, management...